Traphaco named among Vietnam’s 50 Best Listed Firms for the fifth time in a row

On May 29, 2017, Forbes Vietnam announced the "List of Top 50 Best Listed Companies of Vietnam" in 2017. Traphaco is named in the list for the fifth consecutive year.

The "List of Top 50 Best Listed Companies of Vietnam" by Forbes Vietnam ranks the best listed firms in terms of business performance in each sector, whose shares are being traded on the Ho Chi Minh City Stock Exchange (HSX) and the Hanoi Stock Exchange (HNX).

To make this list, Forbes Vietnam used the ranking method of Forbes USA, taking into account the characteristics of listed firms in Vietnam. The data used for the assessment is based on the audited financial statements of the five consecutive years of 2012-2016 (in the case of companies with financial years ending mid-year, Forbes Vietnam used the data of the last accounting year).

Forbes considered all listed stocks on the HSX and HNX and sorted them by sectors. In the preliminary round, loss-incurring companies, those during the delisting process, those with capitalization value and turnover of less than VND300 billion, and subsidiaries that are dependent on the parent company were all eliminated.

In the quantitative round, companies were scored on the basis of double growth in revenue, profitability, ROE, ROC and EPS growth for the period of 2012-2016, using the method of Forbes with the support of the Ban Viet Securities Corporation.

In the qualitative round, Forbes Vietnam independently considered the level of sustainable development of businesses, including: the brand, quality of corporate governance, profit origins, and the prospect of sustainable development. The companies that had repeatedly violated the disclosure obligations of the two stock exchanges and those that were doubted of manipulating stock prices were rejected.

Traphaco is currently the leading company in the field of herbal medicine, with the two top products of Boganic liver tonic Cebraton cerebral tonic. These products rank second and sixth in the Top 20 OTC pharmaceutical products in terms of revenue.

In order to ensure transparency, Traphaco has developed a set of operational regulations and supervision based on the goals of the business. Whenever there is a good solution, a clear goal, Traphaco has used the effective implementation tools.

With the development strategy for the period of 2017-2020 that was approved by the Board of Directors in 2017, Traphaco sets the target to 2020 of reaching market capitalization value of VND10 trillion, total revenue of VND4 trillion, total profit of VND500 billion; Traphaco's technology to be the most modern in the Vietnamese pharmaceutical industry, with a modern management system based on integrated information technology; and Traphaco to have the best working environment in Vietnam.